N. Harbeck, M. Gnant, Breast cancer, The Lancet, 389 (2017) 1134-1150.
 S. Winters, C. Martin, D. Murphy, N.K. Shokar, Breast Cancer Epidemiology, Prevention, and Screening, Prog Mol Biol Transl Sci, 151 (2017) 1-32.
 J.E. Joo, J.G. Dowty, R.L. Milne, E.M. Wong, P.A. Dugue, D. English, J.L. Hopper, D.E. Goldgar, G.G. Giles, M.C. Southey, kConFab, Heritable DNA methylation marks associated with susceptibility to breast cancer, Nat Commun, 9 (2018) 867.
 J.S. de Groot, X. Pan, J. Meeldijk, E. van der Wall, P.J. van Diest, C.B. Moelans, Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report, Cell Oncol (Dordr), 37 (2014) 297-303.
 Hesson LB, Cooper WN, L. F., The role of RASSF1A methylation in cancer, Disease markers, 23 (2007) 73-87.
 Pfeifer GP, D. R., Methylation of the tumor suppressor gene RASSF1A in human tumors, Biochemistry, 70 (2005) 576-583.
 Pfeifer GP, Yoon JH, e.a. Liu L, Methylation of the RASSF1A gene in human cancers, Biological chemistry, 383 (2002) 907-914.
 W. Yeo, W.-L. Wong, N. Wong, B.K. Law, G.M. Tse, S. Zhong, High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer, Pathology, 37 (2005) 125-130.
 X. Cao, Q. Tang, T. Holland-Letz, M. Gundert, K. Cuk, S. Schott, J. Heil, M. Golatta, C. Sohn, A. Schneeweiss, B. Burwinkel, Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals, Int J Mol Sci, 19 (2018).
 Wells GA, Shea B, e.a. OConnell D, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
 T.E. Skvortsova, E.Y. Rykova, S.N. Tamkovich, O.E. Bryzgunova, A.V. Starikov, N.P. Kuznetsova, V.V. Vlassov, P.P. Laktionov, Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation, Br J Cancer, 94 (2006) 1492-1495.
 C. Jeronimo, P. Monteiro, R. Henrique, M. Dinis-Ribeiro, I. Costa, V.L. Costa, L. Filipe, A.L. Carvalho, M.O. Hoque, I. Pais, C. Leal, M.R. Teixeira, D. Sidransky, Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions, Breast Cancer Res Treat, 109 (2008) 27-34.
 M. Kioulafa, L. Kaklamanis, D. Mavroudis, V. Georgoulias, E.S. Lianidou, Prognostic significance of RASSF1A promoter methylation in operable breast cancer, Clin Biochem, 42 (2009) 970-975.
 V. Kloten, B. Becker, K. Winner, M.G. Schrauder, P.A. Fasching, T. Anzeneder, J. Veeck, A. Hartmann, R. Knuchel, E. Dahl, Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening, Breast Cancer Res, 15 (2013) R4.
 Dulaimi E, Hillinck J, e.a. Ibanez de Caceres I, Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients, Clinical cancer research : an official journal of the American Association for Cancer Research, 10 (2004) 6189-6193.
 Shan M, Yin H, e.a. Li J, Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer, Oncotarget, 7 (2016) 18485-18494.
 Y. Ji, H.H. Jin, M.D. Wang, W.X. Cao, J.L. Bao, Methylation of the RASSFIA promoter in breast cancer, Genet Mol Res, 15 (2016).
 H. Donninger, M.D. Vos, G.J. Clark, The RASSF1A tumor suppressor, J Cell Sci, 120 (2007) 3163-3172.
 H.A. Hagrass, H.F. Pasha, M.A. Shaheen, E.H. Abdel Bary, R. Kassem, Methylation status and protein expression of RASSF1A in breast cancer patients, Mol Biol Rep, 41 (2014) 57-65.
 Jones PA, L. PW., Cancer epigenetics comes of age, Nature genetics, 21 (1999) 163-167.
 Y. Jiang, L. Cui, W.D. Chen, S.H. Shen, L.D. Ding, The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data, PLoS One, 7 (2012) e36780.
 R.W. Meng, Y.C. Li, X. Chen, Y.X. Huang, H. Shi, D.D. Du, X. Niu, C. Lu, M.X. Lu, Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis, Sci Rep, 6 (2016) 20756.
 H. Niu, J. Yang, K. Yang, Y. Huang, The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA), Medicine (Baltimore), 96 (2017) e8630.
 C. Shao, W. Dai, H. Li, W. Tang, S. Jia, X. Wu, Y. Luo, The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics, PLoS One, 12 (2017) e0171676.
 N. Pabalan, A. Kunjantarachot, C. Ruangpratheep, H. Jarjanazi, D.M. Christofolini, C.P. Barbosa, B. Bianco, Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis, Gynecol Oncol, 146 (2017) 603-608.